Latest from MSKCC

Andrea Cercek, MD, discusses targeted strategies in BRAF-mutant metastatic colorectal cancer.
Neil H. Segal, MD, PhD, discusses the current role of immunotherapy in colorectal cancer and the work being done to define its role in earlier-line settings and among patients with microsatellite stable disease.
James J. Harding, MD, discusses the evolving treatment landscape in frontline hepatocellular carcinoma and ongoing trials that may revolutionize the space.
Andrea Cercek, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the impact of tumor sidedness on frontline treatment decisions in metastatic colorectal cancer (mCRC).
Ghassan K. Abou-Alfa, MD, discusses the treatment options that have emerged in advanced hepatocellular carcinoma and the work being done to determine optimal sequencing strategies.
David H. Ilson, MD, PhD, discusses TKI combinations under investigation in gastric cancer.
David H. Ilson, MD, PhD, discusses the treatment landscape of advanced gastric cancer and the research being done to define a role for novel agents in this space.
Andrea Cercek, MD, shares insight on treatment selection, the importance of molecular testing, and unanswered questions with tumor sidedness in patients with newly diagnosed metastatic colorectal cancer.
Publication Bottom Border
Border Publication